Antibody against pancreatic cancer stem cells

An antibody against pancreatic cancer stem cells, comprising a heavy chain variable region including heavy chain CDRs as depicted in HCDR1 to HCDR3 below, and a light chain variable region including light chain CDRs as depicted in LCDR1 to LCDR3 below:

• HCDR1 including an amino acid sequence from position 26 to position 35, from position 31 to position 35, from position 26 to position 33, or from position 27 to position 35 of SEQ ID NO:
• 5;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions,
• HCDR2 including an amino acid sequence from position 47 to position 66, from position 50 to position 66, from position 51 to position 58, or from position 47 to position 60 of SEQ ID NO:
• 5;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions,
• HCDR3 including an amino acid sequence from position 97 to position 111, from position 99 to position 111, or from position 98 to position 111 of SEQ ID NO:
• 5;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions,
• LCDR1 including an amino acid sequence from position 24 to position 34, from position 27 to position 32, or from position 27 to position 34 of SEQ ID NO:
• 6;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions,
• LCDR2 including an amino acid sequence from position 46 to position 56, from position 50 to position 56, or from position 50 to position 51 of SEQ ID NO:
• 6;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions, and
• LCDR3 including an amino acid sequence from position 89 to position 98 or from position 89 to position 97 of SEQ ID NO:
• 6;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions.

An anti-EpCAM antibody, comprising a heavy chain variable region including heavy chain CDRs as depicted in HCDR1 to HCDR3 below, and a light chain variable region including light chain CDRs as depicted in LCDR1 to LCDR3 below:

• HCDR1 including an amino acid sequence from position 26 to position 35, from position 31 to position 35, from position 26 to position 33, or from position 27 to position 35 of SEQ ID NO:
• 7;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions,
• HCDR2 including an amino acid sequence from position 47 to position 66, from position 50 to position 66, from position 51 to position 58, or from position 47 to position 61 of SEQ ID NO:
• 7;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions,
• HCDR3 including an amino acid sequence from position 97 to position 112, from position 99 to position 112, or from position 98 to position 112 of SEQ ID NO:
• 7;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions,
• LCDR1 including an amino acid sequence from position 24 to position 34, from position 27 to position 32, or from position 27 to position 34 of SEQ ID NO:
• 8;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions,
• LCDR2 including an amino acid sequence from position 46 to position 56, from position 50 to position 56, or from position 50 to position 51 of SEQ ID NO:
• 8;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions, and
• LCDR3 including an amino acid sequence from position 89 to position 97 or from position 89 to position 96 of SEQ ID NO:
• 8;
• an amino acid sequence having the amino acid sequence in which one to several amino acids are substituted, deleted, added, and/or inserted;
• an amino acid sequence having 85% or more sequence identity to the amino acid sequence;
• or an amino acid sequence encoded by a polynucleotide that specifically hybridizes to a polynucleotide including a base sequence complementary to a base sequence encoding the amino acid sequence under stringent conditions.